文献速递核素与放射性配体治疗肿瘤 PET/CT

炎症指数与68Ga-DOTATOC PET摄取及体积参数预测90Y-DOTATOC治疗神经内分泌肿瘤结局

Inflammation-Based Index and 68Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC.
PubMed 文献 · J Nucl Med · 2019-12-05

结果显示,基线SUVmean>13.7与更好生存相关,肿瘤体积>578 cm3及IBI升高与更差总生存相关,复合评分可进一步分层患者。

要点

  • 基线SUVmean>13.7与更好生存相关(HR 0.45,P=0.024)。
  • 基线IBI升高与更差总生存相关(HR 3.90,P=0.001)。
  • 早期 interim PET的SUVmean下降>17%与更差生存相关(HR 2.29,P=0.024)。

核心结论

  • 基线IBI正常且68Ga-DOTATOC肿瘤摄取高预测90Y-DOTATOC治疗的NET患者结局更好。

主要发现

  • 中位无进展生存期和总生存期分别为13.9个月和22.3个月。
  • 基线SUVmean高于13.7(第75百分位)与更好生存相关(HR 0.45,P=0.024)。
  • 68Ga-DOTATOC高摄取肿瘤体积高于578 cm3(第75百分位)与更差总生存相关(HR 2.18,P=0.037)。
  • 基线IBI升高与更差总生存相关(HR 3.90,P=0.001)。
  • 多变量分析证实总生存与SUVmean(P=0.016)及IBI(P=0.015)独立相关。

关键数值与推荐

  • 基线SUVmean阈值13.7(第75百分位)用于区分生存。
  • 基线肿瘤体积阈值578 cm3(第75百分位)用于区分总生存。
  • 早期 interim PET的SUVmean下降阈值17%(第75百分位)与更差生存相关。

临床怎么用

  • 基线IBI和68Ga-DOTATOC PET肿瘤摄取参数可用于90Y-DOTATOC治疗的个体化决策。
  • 早期 interim 68Ga-DOTATOC PET未提供用于治疗个体化的信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We performed post hoc analyses on the utility of pretherapeutic and early interim 68Ga-DOTATOC PET tumor uptake and volumetric parameters and a recently proposed biomarker, the inflammation-based index (IBI), for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumor (NET) patients treated with 90Y-DOTATOC in the setting of a prospective phase II trial. Methods: Forty-three NET patients received up to 4 cycles of 90Y-DOTATOC at 1.85 GBq/m2/cycle with a maximal kidney biologic effective dose of 37 Gy. All patients underwent 68Ga-DOTATOC PET/CT at baseline and 7 wk after the first PRRT cycle. 68Ga-DOTATOC-avid tumor lesions were semiautomatically delineated using a customized SUV threshold-based approach. PRRT response was assessed on CT using RECIST 1.1. Results: Median progression-free survival and overall survival (OS) were 13.9 and 22.3 mo, respectively. An SUVmean higher than 13.7 (75th percentile) was associated with better survival (hazard ratio [HR], 0.45; P = 0.024), whereas a 68Ga-DOTATOC-avid tumor volume higher than 578 cm3 (75th percentile) was associated with worse OS (HR, 2.18; P = 0.037). Elevated baseline IBI was associated with worse OS (HR, 3.90; P = 0.001). Multivariate analysis corroborated independent associations between OS and SUVmean (P = 0.016) and IBI (P = 0.015). No significant correlations with progression-free survival were found. A composite score based on SUVmean and IBI allowed us to further stratify patients into 3 categories with significantly different survival. On early interim PET, a decrease in SUVmean of more than 17% (75th percentile) was associated with worse survival (HR, 2.29; P = 0.024). Conclusion: Normal baseline IBI and high 68Ga-DOTATOC tumor uptake predict better outcome in NET patients treated with 90Y-DOTATOC. This method can be used for treatment personalization. Interim 68Ga-DOTATOC PET does not provide information for treatment personalization.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pauwels E, Van Binnebeek S, Vandecaveye V, et al. Inflammation-Based Index and 68Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC. J Nucl Med. 2019. PMID: 31806775. doi:10.2967/jnumed.119.236935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。